Tuesday, November 9, 2010

Drugmakers catch Ablexis mouse in $50M+ deal

Five of the world’s 15 largest pharmaceutical companies, including Pfizer Inc., promised seven-figure upfront payments each to venture-funded Ablexis LLC in a unique deal for a finely tuned transgenic mouse that could make it easier to discover and develop antibody drugs.
The companies each also will make eight-figure payments to Ablexis once the company, started in December and housed in the FibroGen building in San Francisco’s Mission Bay, delivers its AlivaMab mouse strains.

No comments:

Post a Comment